Nama's AI scorecard currently rates Haemonetics Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is HAE's P/E ratio?

Haemonetics trades at a trailing price-to-earnings ratio of 23.6.

When does HAE report earnings?

Haemonetics's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.36.

What is the HAE price target?

The median analyst price target from 10 analysts is $127.50, with a range of $86.00 – $142.00.

Is HAE Shariah compliant?

Nama's AAOIFI-style screen reads Haemonetics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Haemonetics (HAE)

Healthcare · Medical Devices · NYSE

Haemonetics (HAE) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $5.46B, a trailing price-to-earnings ratio of 23.6 and a free-cash-flow yield of 4.6%. Over the most recent reported fiscal year, revenue declined 2.0% and free cash flow per share grew 95.9%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.6/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +51.6% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-9.1%

How far the last close sits under the highest price of the past five years.

Market cap	$5.46B
Trailing P/E	23.6
Price / book	6.5
Price / sales	4.0
FCF yield	4.6%
Dividend yield	—
Gross margin	59.0%
Operating margin	18.1%
Net margin	7.1%
Revenue growth (YoY)	-2.0%
Revenue growth (3-yr annual)	+4.5%
EPS growth (YoY)	+8.8%
FCF/share growth (YoY)	+95.9%
Beta	0.6
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

HAE earnings

Next report: Feb 4, 2027 (Q3 2027, EPS estimate $1.36). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2027	Nov 5, 2026	$1.35	$1.29	+4.7%	$357.76M
Q1 2027	Aug 6, 2026	$1.14	$1.08	+5.6%	$339.38M
Q4 2026	May 7, 2026	$1.29	$1.27	+1.6%	$346.35M
Q3 2026	Feb 5, 2026	$1.31	$1.25	+4.8%	$338.97M

HAE analyst price target

Median target $127.50 from 10 analysts, ranging $86.00 – $142.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live HAE data on Nama Insights →

HAE FAQ

Is HAE a buy?: Nama's AI scorecard currently rates Haemonetics Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is HAE's P/E ratio?: Haemonetics trades at a trailing price-to-earnings ratio of 23.6.
When does HAE report earnings?: Haemonetics's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $1.36.
What is the HAE price target?: The median analyst price target from 10 analysts is $127.50, with a range of $86.00 – $142.00.
Is HAE Shariah compliant?: Nama's AAOIFI-style screen reads Haemonetics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.